Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 44

Sort by

Sort Order Select

Journal Articles

The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Shilin Gan, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2025-2377

Published: 2025

Journal Articles

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

Fan Yang, Rui Liu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Haifeng Wu, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 2368.

https://doi.org/10.1182/blood-2025-2368

Published: 2025

Journal Articles

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2025-3708

Published: 2025

Journal Articles

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Rui Liu, Danyang Li, Zhonghua Fu, Fan Yang, Miaomiao Cao, Lixia Ma, Yuelu Guo, Alex H. Zhang, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 3706.

https://doi.org/10.1182/blood-2025-3706

Published: 2025

Journal Articles

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Miaomiao Cao, Hui Shi, Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 5489.

https://doi.org/10.1182/blood-2025-5489

Published: 2025

Journal Articles

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study

Huiqiang Huang, Xuan-Ye Zhang, Jicheng Hong, Gao Yan, Peng Liu, Kai Hu, Jingping Pi, Rui Liu, Haoqing Chen, Jialing Zhuang

Blood (2025) 146 (Supplement 1): 7208.

https://doi.org/10.1182/blood-2025-7208

Published: 2025

Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Blood (2025) 146 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2025-1878

Published: 2025

Journal Articles

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 672.

https://doi.org/10.1182/blood-2025-672

Published: 2025

Journal Articles

Kte-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: 6-month analysis of a phase II multicenter trial

Meng Lv, Hao Jiang, Yuhua Li, Yicheng Zhang, Jie Jin, Hongsheng Zhou, Kailin Xu, Mingfeng Zhao, Xin Du, Kai Hu, Jun Hu, Jinghua Zhao, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2025-1563

Published: 2025

Journal Articles

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

Fan Yang, Rui Liu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Haifeng Wu, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2025-5484

Published: 2025

Journal Articles

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Danyang Li, Biping Deng, Qinlong Zheng, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 7259.

https://doi.org/10.1182/blood-2025-7259

Published: 2025

Journal Articles

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Blood (2025) 146 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2025-1042

Published: 2025

Journal Articles

The preliminary results of MRG001-C002: A phase II Study of MRG001 combined with Orelabrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Keshu Zhou, Xingchen Liu, Xueli Jiao, Qing Zhang, xu Ji, Qianying Pan, Kai Hu, Bian Wei, Lin Chen, Fenghua Gao, Minghui Li, Quande Lin, Ruihua Mi, Fengdi Wang, Haiying Wang, Qinglan Zhang, Lihua Dong

Blood (2025) 146 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2025-1914

Published: 2025

Journal Articles

Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

Biping Deng, Zhaoli Liu, Xiaoming Qu, Yu'e Zhang, Zhongxin Zhang, Rong Luan, Lingli Zhang, Ming Ma, Xiai Wu, Rui Liu, Alex H. Chang, Kai Hu, Chunrong Tong

Blood (2024) 144 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2024-203423

Published: 2024

Journal Articles

EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Mingyuan Sun, Lugui Qiu, Keshu Zhou, Kai Hu, Chunkang Chang, Dong Wu, Zhenling Li, Ming Gong, Wenjun Zhang, Daniel Yang, Jiali Lu, Junyuan Qi

Blood (2024) 144 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2024-193606

Published: 2024

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Journal Articles

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6183.

https://doi.org/10.1182/blood-2024-202415

Published: 2024

Journal Articles

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Lixia Ma, Rui Liu, Fan Yang, Yuelu Guo, Yimeng Dou, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2024-200523

Published: 2024

Journal Articles

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2024-202286

Published: 2024

Journal Articles

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Bian Wei, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Qinlong Zheng, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6549.

https://doi.org/10.1182/blood-2024-206676

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

Kte-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: 6-month analysis of a phase II multicenter trial

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

The preliminary results of MRG001-C002: A phase II Study of MRG001 combined with Orelabrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only